The Impact of Peripheral Vascular Motion on Acute Drug Retention of Intravascular Devices.

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Engineering and Technology Pub Date : 2025-02-13 DOI:10.1007/s13239-025-00776-z

Trey Ursillo, Kayla Lowry, Catherine Allred, Mollie Phillips, Linda B Liu, Danyi Chen, Saami K Yazdani

{"title":"The Impact of Peripheral Vascular Motion on Acute Drug Retention of Intravascular Devices.","authors":"Trey Ursillo, Kayla Lowry, Catherine Allred, Mollie Phillips, Linda B Liu, Danyi Chen, Saami K Yazdani","doi":"10.1007/s13239-025-00776-z","DOIUrl":null,"url":null,"abstract":"Purpose: This goal of this study was to determine the impact of vascular motion on acute drug transfer and retention of drug-coated balloons (DCB) or drug-eluting stents (DES).Methods: Commercially available paclitaxel DCBs (Lutonix & IN.PACT) and a paclitaxel DES (Zilver) were subjected to physiological flow and vascular motion conditions using a peripheral-simulating benchtop bioreactor system. Each DCB- or DES-treated artery was subjected to three sets of movement parameters including pulsatile flow with no twisting/bending (P1), pulsatile flow with 16.8° twist, 25° bend and 3.2 mm compression (P2), and pulsatile flow with 68° twist, 35° bend, 21 mm compression (P3). After 24 h, the treated segments were removed and paclitaxel concentrations were measured using pharmacokinetic analysis.Results: In the group of arteries treated with the Lutonix DCB, there was a significant decrease in arterial paclitaxel concentrations between the P1 and both the P2 and P3 moving parameters (P1 = 404 ± 195 ng/mg, P2 = 14.9 ± 9.92 ng/mg, P3 = 19.2 ± 15.4 ng/mg; P1-P2 p = 0.007, P1-P3 p = 0.005). For the IN.PACT DCB group, no differences in the mean arterial paclitaxel concentrations were observed for the various movements (p = 0.55). Lastly, in the Zilver DES group, differences were only measured between the P2 and P3 moving parameters (P2 = 84.8 ± 32.7 ng/mg, P3 = 0.11 ± 0.06 ng/mg; P2-P3 p = 0.01).Conclusion: Acute retention of arterial paclitaxel levels can be adversely impacted by vascular movement in both DES- and DCB- treated arteries.","PeriodicalId":54322,"journal":{"name":"Cardiovascular Engineering and Technology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Engineering and Technology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13239-025-00776-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This goal of this study was to determine the impact of vascular motion on acute drug transfer and retention of drug-coated balloons (DCB) or drug-eluting stents (DES).

Methods: Commercially available paclitaxel DCBs (Lutonix & IN.PACT) and a paclitaxel DES (Zilver) were subjected to physiological flow and vascular motion conditions using a peripheral-simulating benchtop bioreactor system. Each DCB- or DES-treated artery was subjected to three sets of movement parameters including pulsatile flow with no twisting/bending (P1), pulsatile flow with 16.8° twist, 25° bend and 3.2 mm compression (P2), and pulsatile flow with 68° twist, 35° bend, 21 mm compression (P3). After 24 h, the treated segments were removed and paclitaxel concentrations were measured using pharmacokinetic analysis.

Results: In the group of arteries treated with the Lutonix DCB, there was a significant decrease in arterial paclitaxel concentrations between the P1 and both the P2 and P3 moving parameters (P1 = 404 ± 195 ng/mg, P2 = 14.9 ± 9.92 ng/mg, P3 = 19.2 ± 15.4 ng/mg; P1-P2 p = 0.007, P1-P3 p = 0.005). For the IN.PACT DCB group, no differences in the mean arterial paclitaxel concentrations were observed for the various movements (p = 0.55). Lastly, in the Zilver DES group, differences were only measured between the P2 and P3 moving parameters (P2 = 84.8 ± 32.7 ng/mg, P3 = 0.11 ± 0.06 ng/mg; P2-P3 p = 0.01).

Conclusion: Acute retention of arterial paclitaxel levels can be adversely impacted by vascular movement in both DES- and DCB- treated arteries.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Engineering and Technology Engineering-Biomedical Engineering

CiteScore

4.00

自引率

0.00%

发文量

期刊介绍： Cardiovascular Engineering and Technology is a journal publishing the spectrum of basic to translational research in all aspects of cardiovascular physiology and medical treatment. It is the forum for academic and industrial investigators to disseminate research that utilizes engineering principles and methods to advance fundamental knowledge and technological solutions related to the cardiovascular system. Manuscripts spanning from subcellular to systems level topics are invited, including but not limited to implantable medical devices, hemodynamics and tissue biomechanics, functional imaging, surgical devices, electrophysiology, tissue engineering and regenerative medicine, diagnostic instruments, transport and delivery of biologics, and sensors. In addition to manuscripts describing the original publication of research, manuscripts reviewing developments in these topics or their state-of-art are also invited.